Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2013

View Archived Issues

Preclinical and clinical safety data for EBI-005 presented

GTx-758 effectively suppresses testosterone in males with prostate cancer

BL-8030 shows potency, selectivity and a promising pharmacokinetic profile

Merck KGaA presents novel TGFR-1 inhibitor with in vivo antitumor activity

Lexicon advances LX-4211 to expansion portion of phase II trial

PRELUDE study of enzastaurin fails to meet primary endpoint

ALS Emergency Treatment Fund and Denovo Biomarkers establish partnership

Arno Therapeutics and Clarient to develop companion diagnostic

Serum CYPA as a novel biomarker of atherosclerotic diseases

Researchers develop novel vaccine with the potential to block tumor foci formation

Dainippon Sumitomo Pharma reflects on accomplishments of fiscal 2012

Chinese group presents new DHODH inhibitors

Novel compounds inhibiting deubiquitinating activity patented by Vivolux

Sirtris Pharmaceuticals discloses new hSIRT1 activators

Bayer Intellectual Property divulges novel HIF-1 inhibitors

Pan-genomic anti-HCV activity disclosed for tetrahydroquinolines

Novavax commences animal testing with H7N9 VLP influenza vaccine

FDA accepts Biogen Idec's Eloctate BLA for filing

Starpharma's SPL-7013 shows potential to treat viral conjunctivitis

Mirna Therapeutics advances miRNA MRX-34 into phase I

MorphoSys begins new phase II trial of MOR-208 in NHL

Actavis and Warner Chilcott discuss potential business combination

Relypsa completes enrollment in pivotal phase III trial of patiromer

FDA grants priority review to simeprevir NDA

FDA approves first nimodipine oral solution

Sorrento Therapeutics and Igdrasol acquire E.U. rights to Cynviloq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...